2026年上半年信息
中国中药(00570)公告显示，2026年上半年公司实现营收54.38亿元，同比下降27.1%。经调整净亏损7.76亿元，同比下降619.3%。毛利25.81亿元，较去年同期下滑29.0%，毛利率约为47.5%，较去年同期下降1.2个百分点。成本方面，销售及分销成本18.90亿元，同比下降26.1%；行政支出5.52亿元，同比增长10.3%；研发投入1.88亿元，同比下降26.8%。公司整体净利率为-15.3%，比去年同期下降13.4个百分点。
业务分项
• 中药材生产及经营：营收1.90亿元，同比下降57.5%，毛利率4.8%，较上年同期减少5.0个百分点。 • 中药饮片：营收15.60亿元，同比下降2.3%，毛利率24.9%，同比上升1.3个百分点。 • 中药配方颗粒：营收19.33亿元，同比下降35.4%，毛利率56.3%，同比上升0.7个百分点。 • 中成药：营收16.63亿元，同比下降28.0%，毛利率64.0%，同比下降1.6个百分点。 • 中医药大健康：营收0.93亿元，同比下降23.5%，毛利率33.8%，同比上升3.0个百分点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.